KUALA LUMPUR, Nov 15 -- Underdog Pharmaceuticals Inc (Underdog) and SENS Research Foundation (SRF) have launched Underdog and announced the completion of its seed round.
The seed round provides US$3.95 million to promote Underdog’s development of disease-modifying treatments for atherosclerosis and other age-related diseases. (US$1 = RM4.15)
Underdog was built from an SRF flagship programme that has driven two years of applied development, designed to explore and repair the underlying causes of cardiovascular disease.
Underdog’s research has combined computational and synthetic chemistry programmes to create custom-engineered cyclodextrins (polysaccharides with known industrial and pharmaceutical excipient uses) to capture, and remove from cells, oxidised cholesterol derivatives.
The agreement between the organisations will provide equity, royalties and milestones for the future support of SRF programmes.
The Underdog round is led by Michael Greve’s Kizoo Technology Capital, part of the Forever Healthy Group and one of the premier organisations focusing on accelerating rejuvenation biotechnologies.
It also includes Oculus co-founder Michael Antonov through Tubus LLC and financier Harald McPike through Chambray Worldwide Ltd.
-- BERNAMA
No comments:
Post a Comment